Drug intelligence / Profile preview

DGG-KLH

Development stage: Preclinical
Lead developer: Medical University of Vienna
Modality: Recombinant Proteins and Enzymes, Peptides, Vaccines & Immunotherapeutics
Administration: Intradermal, Subcutaneous

Overview

**DGG-KLH** is an experimental active cancer-vaccine conjugate comprising the DGG peptide mimotope of the disialoganglioside **GD2** covalently coupled to keyhole limpet hemocyanin. DGG was selected using the anti-GD2 chimeric monoclonal antibody ch14.18 as a structural mimic of its GD2 epitope. In BALB/c mice, DGG-KLH induced IgG antibodies that recognized purified GD2 and GD2 expressed by neuroblastoma and melanoma cells, supporting its use as a preclinical immunotherapy approach for GD2-positive neuroectodermal tumors.

Other names: DGG-KLH

Targets

GD2

Beyond the preview

Go deeper on DGG-KLH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DGG-KLH.

Explore the full profile